The EU currently encourages member states to assess the feasibility and effectiveness of a risk-organized PCa screening by utilizing PSA testing and magnetic resonance imaging (MRI) scanning as a follow-up measure [3,4,5,6]. The gene discussed is KLK3; the disease is posterior cortical atrophy.